BTIG Maintains Buy on Carlsmed, Raises Price Target to $24

BTIG analyst Ryan Zimmerman has reiterated a Buy rating on Carlsmed (NASDAQ: CARL) and increased the price target from $23 to $24. This adjustment reflects positive sentiment towards the company's performance and future prospects.